EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study

Kristian Reich, Jonathan I Silverberg iD, Kim A Papp iD, Mette Deleuran iD, Norito Katoh, Bruce Strober iD, Lisa A Beck iD, Marjolein de Bruin-Weller, Thomas Werfel, Fan Zhang, Pinaki Biswas, Marco D DiBonaventura und 5 weitere

Journal of the European Academy of Dermatology and Venereology · 2023-10 · 37 (10) · 2056-2066

DOI: 10.1111/jdv.19280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 11.07.2023. Verfasst von Kristian Reich und 16 weiteren Autor:innen. Beteiligte Einrichtung: University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Inc., Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Abrocitinib improved signs and symptoms of moderate‐to‐severe atopic dermatitis (AD) at 12 or 16 weeks in phase 3 studies with a manageable safety profile. Further understanding of the abrocitinib long‐term efficacy and safety profile is important for its appropriate use in treating chronic AD.

Objective

To evaluate the abrocitinib efficacy up to 48 weeks and long‐term safety in patients with moderate‐to‐severe AD.

Methods

JADE EXTEND (NCT03422822) is an ongoing, phase 3, long‐term extension study that enrolled patients from previous abrocitinib AD trials. This analysis focusses on patients from the phase 3 JADE MONO‐1 (NCT03349060), JADE MONO‐2 (NCT03575871) and JADE COMPARE (NCT03720470) studies who completed the full treatment period of placebo or abrocitinib (200 mg or 100 mg once daily) and subsequently entered JADE EXTEND. Efficacy endpoints included the proportion of patients achieving skin clearance (Investigator's Global Assessment [IGA] 0/1 [clear/almost clear]; ≥75% improvement in Eczema Area and Severity Index [EASI‐75]) and itch response (Peak Pruritus Numerical Rating Scale [PP‐NRS] severity ≥4‐point improvement). Safety endpoints included treatment‐emergent adverse events (TEAEs), serious TEAEs and TEAEs leading to discontinuation. Data cut‐off: April 22, 2020.

Results

As of the data cut‐off, ~70% and ~45% of patients received abrocitinib for ≥36 and ≥48 weeks, respectively. Nasopharyngitis, atopic dermatitis, nausea and upper respiratory tract infections were the most frequent TEAEs. Serious TEAEs occurred in 7% and 5% and TEAEs leading to study discontinuation occurred in 9% and 7% of patients receiving abrocitinib 200 mg and 100 mg, respectively. Week 48 efficacy responses with abrocitinib 200 mg and 100 mg were as follows: IGA 0/1 52% and 39%; EASI‐75 82% and 67%, and PP‐NRS severity ≥4‐point improvement 68% and 51%.

Conclusions

In patients with moderate‐to‐severe AD, long‐term abrocitinib treatment resulted in clinically meaningful skin and pruritus improvement. The long‐term safety profile was manageable and consistent with previous reports.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansDouble-Blind MethodImmunoglobulin APruritusSeverity of Illness IndexTreatment OutcomeClinical Trials, Phase III as TopicPyrimidinesSulfonamides

Substanzen

Immunoglobulin AabrocitinibPyrimidinesSulfonamides

Autor:innen und Institutionen

  • University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • MoonLake Immunotherapeutics AG, Zug, Switzerland.
  • The George Washington University School of Medicine & Health Sciences, Washington, District of Columbia, USA.
  • Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada.
  • The University of Toronto, Toronto, Ontario, Canada.
  • Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Jonathan I Silverberg, Kim A Papp, Mette Deleuran, Bruce Strober, Lisa A Beck

Förderung

  • Pfizer Inc.
  • Pfizer

Zitieren

APA

Reich, K., Silverberg, J. I., Papp, K. A., Deleuran, M., Katoh, N., Strober, B., Beck, L. A., de Bruin-Weller, M., Werfel, T., Zhang, F., Biswas, P., DiBonaventura, M. D., Chan, G., Johnson, S., Farooqui, S. A., Kerkmann, U., & Clibborn, C. (2023). Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology, 37(10), 2056-2066. https://doi.org/10.1111/jdv.19280

Vancouver

Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, et al. Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology. 2023;37(10):2056-2066. doi:10.1111/jdv.19280

BibTeX
@article{Reich2023,
  author = {Reich, Kristian and Silverberg, Jonathan I and Papp, Kim A and Deleuran, Mette and Katoh, Norito and Strober, Bruce and Beck, Lisa A and de Bruin-Weller, Marjolein and Werfel, Thomas and Zhang, Fan and Biswas, Pinaki and DiBonaventura, Marco D and Chan, Gary and Johnson, Susan and Farooqui, Saleem A and Kerkmann, Urs and Clibborn, Claire},
  title = {Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  volume = {37},
  number = {10},
  pages = {2056--2066},
  doi = {10.1111/jdv.19280}
}
Kostenlos starten →